Canterbury DHB

Context

References

  1. Marsh, J.C. and D.H. Bevan, Haematological care of the Jehovah's Witness patient. Br J Haematol, 2002. 119(1): p. 25-37.
  2. 2011 Report of Jehovah's Witnesses Worldwide. 2012; Available from: http://www.watchtower.org/e/statistics/worldwide_report.htm.
  3. Berend, K. and M. Levi, Management of adult Jehovah's Witness patients with acute bleeding. Am J Med, 2009. 122(12): p. 1071-6.
  4. ANZSBT, ANZSBT Guidelines for the Administration of Blood Products, 2011.
  5. Haselbeck, A., Epoetins: differences and their relevance to immunogenicity. Curr Med Res Opin, 2003. 19(5): p. 430-2.
  6. Gohel, M.S., et al., How to approach major surgery where patients refuse blood transfusion (including Jehovah's Witnesses). Ann R Coll Surg Engl, 2005. 87(1): p. 3-14.
  7. Authority, N.B. Patient Blood Management Guidelines: Module 2 - Perioperative. 2012; Patient Blood Management Guidelines. ]. Available from: www.blood.gov.au/system/files/documents/pbm-module-2.pdf.
  8. Adelola, O.A., I. Ahmed, and J.E. Fenton, Management of Jehovah's Witnesses in otolaryngology, head and neck surgery. Am J Otolaryngol, 2008. 29(4): p. 270-8.
  9. Ltd, B.H. Tisseel Data Sheet. 2010; Available from: http://www.medsafe.govt.nz/profs/Datasheet/t/TisseelFibrinSealant.pdf.
  10. Carson, J.L., et al., Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med, 2011. 365(26): p. 2453-62.
  11. Roger Hall, R.M., Medical Laboratory Haematology. Second ed1991: Butterworth Heinemann.
  12. Ladas, S.D., et al., Does recombinant human erythropoietin accelerate correction of post-ulcer-bleeding anaemia? A pilot study. World J Gastroenterol, 2004. 10(4): p. 586-9.
  13. de Andrade, J.R., et al., Baseline hemoglobin as a predictor of risk of transfusion and response to Epoetin alfa in orthopedic surgery patients. Am J Orthop (Belle Mead NJ), 1996. 25(8): p. 533-42.
  14. Hebert, P.C., et al., A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med, 1999. 340(6): p. 409-17.
  15. Alvarez, G., P.C. Hebert, and S. Szick, Debate: transfusing to normal haemoglobin levels will not improve outcome. Crit Care, 2001. 5(2): p. 56-63.
  16. Price, S., J.R. Pepper, and S.I. Jaggar, Recombinant human erythropoietin use in a critically ill Jehovah's Witness after cardiac surgery. Anesth Analg, 2005. 101(2): p. 325-7, table of contents.
  17. Corwin, H.L., et al., Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA, 2002. 288(22): p. 2827-35.
  18. Van Wolfswinkel, M.E., et al., Maternal mortality and serious maternal morbidity in Jehovah's Witnesses in The Netherlands. BJOG, 2009. 116(8): p. 1103-8; discussion 1108-10.
  19. Sheehan, S.R. and D.J. Murphy, A pregnant Jehovah's Witness. BMJ, 2008. 337: p. a1935.

About this Canterbury DHB document (47859):

Document Owner:

Julia Czuprynska and Richard Seigne (see Who's Who)

Issue Date:

August 2014

Next Review:

August 2016

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 47859